Benzinga | Jan 20, 2022 04:50AM EST

BMO Capital Upgrades Vertex Pharmaceuticals to Outperform, Raises Price Target to $274

BMO Capital analyst Evan Seigerman upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Market Perform to Outperform and raises the price target from $202 to $274.